Table 4.
Univariate and multivariate analysis of factors associated with HCC recurrence in HBeAg negative patients with low viral load
| Factor | n | Recurrence rate (%) | Univariate analysis (p value) | Multivariate Analyses (p value) | Hazard ratio | 95% CI | |
|---|---|---|---|---|---|---|---|
|
| |||||||
| 1-year | 3-year | ||||||
| Gender | 0.331 | NA | NA | NA | |||
| Male | 253 | 24.5 | 43.5 | ||||
| Female | 50 | 16.0 | 40.0 | ||||
| Age | 0.670 | NA | NA | NA | |||
| < 50 | 118 | 22.9 | 39.8 | ||||
| 50-59 | 105 | 24.8 | 45.7 | ||||
| ≥ 60 | 80 | 21.3 | 43.8 | ||||
| Cirrhosis | 0.098 | 0.075 | 1.550 | 0.957-2.509 | |||
| Yes | 170 | 24.7 | 47.6 | ||||
| No | 133 | 21.1 | 36.8 | ||||
| Diabetes | 0.001 | 0.188 | 1.649 | 0.783-3.472 | |||
| Yes | 13 | 15.4 | 84.6 | ||||
| No | 290 | 23.4 | 41.0 | ||||
| Serum HBsAg level (S/CO) | 0.014 | 0.107 | 1.549 | 0.910-2.638 | |||
| < 2000 | 84 | 19.0 | 31.0 | ||||
| ≥ 2000 | 219 | 24.7 | 47.5 | ||||
| Serum HBV DNA level (IU/ml) | 0.550 | NA | NA | NA | |||
| < 1000 | 273 | 23.1 | 42.5 | ||||
| 1000-1999 | 30 | 23.3 | 46.7 | ||||
| ALT (U/L) | 0.186 | NA | NA | NA | |||
| ≤ 41 | 228 | 23.7 | 40.4 | ||||
| > 41 | 75 | 21.3 | 50.7 | ||||
| AST (U/L) | 0.045 | 0.483 | 0.818 | 0.465-1.436 | |||
| ≤ 37 | 226 | 20.4 | 39.8 | ||||
| > 37 | 77 | 31.2 | 51.9 | ||||
| TBIL (μmol/L) | 0.918 | NA | NA | NA | |||
| ≤ 18.8 | 252 | 22.2 | 43.3 | ||||
| > 18.8 | 51 | 27.5 | 41.2 | ||||
| γ-GT (U/L) | < 0.001 | 0.001 | 2.346 | 1.430-3.849 | |||
| ≤ 61 | 181 | 17.1 | 30.4 | ||||
| > 61 | 122 | 32.0 | 61.5 | ||||
| ALP (U/L) | 0.103 | NA | NA | NA | |||
| ≤ 129 | 269 | 21.9 | 41.6 | ||||
| > 129 | 34 | 32.4 | 52.9 | ||||
| AFP (μg/L) | 0.140 | NA | NA | NA | |||
| ≤ 20 | 135 | 14.8 | 40.0 | ||||
| > 20 | 168 | 29.8 | 45.2 | ||||
| ALB (g/L) | 0.285 | NA | NA | NA | |||
| < 34 | 2 | 0.0 | 0.0 | ||||
| ≥ 34 | 301 | 23.3 | 43.2 | ||||
| Prealbumin (mg/L) | 0.006 | 0.383 | 1.265 | 0.746-2.147 | |||
| < 170 | 59 | 35.6 | 57.6 | ||||
| ≥ 170 | 244 | 20.1 | 39.3 | ||||
| PT (s) | 0.392 | NA | NA | NA | |||
| ≤ 13 | 270 | 21.9 | 42.2 | ||||
| > 13 | 33 | 33.3 | 48.5 | ||||
| WBC (*109/L) | 0.825 | NA | NA | NA | |||
| < 4 | 51 | 25.5 | 45.1 | ||||
| ≥ 4 | 252 | 22.6 | 42.5 | ||||
| PLT (*109/L) | 0.805 | NA | NA | NA | |||
| < 100 | 44 | 25.0 | 45.5 | ||||
| ≥ 100 | 259 | 22.8 | 42.5 | ||||
| Tumor number | < 0.001 | 0.941 | 1.020 | 0.606-1.716 | |||
| single | 250 | 19.2 | 38.4 | ||||
| multiple | 53 | 41.5 | 64.2 | ||||
| Tumor size (cm) | < 0.001 | 0.230 | 1.178 | 0.901-1.541 | |||
| ≤ 3 | 95 | 8.4 | 30.5 | ||||
| 3~5 | 99 | 20.2 | 39.4 | ||||
| 5~10 | 82 | 35.4 | 56.1 | ||||
| > 10 | 27 | 48.1 | 59.3 | ||||
| Capsule formation | 0.002 | 0.007 | 0.488 | 0.291-0.819 | |||
| Yes | 244 | 20.9 | 39.8 | ||||
| No | 59 | 32.2 | 55.9 | ||||
| Edmonson grading | 0.071 | 0.649 | 0.897 | 0.563-1.431 | |||
| I | 6 | 16.7 | 33.3 | ||||
| II | 70 | 10.0 | 32.9 | ||||
| III | 216 | 25.9 | 45.4 | ||||
| IV | 11 | 54.5 | 63.6 | ||||
| Portal vein invasion | < 0.001 | 0.812 | 1.080 | 0.571-2.043 | |||
| Yes | 29 | 55.2 | 79.3 | ||||
| No | 274 | 19.7 | 39.1 | ||||
| Microvascular invasion | < 0.001 | 0.001 | 2.215 | 1.367-3.589 | |||
| Yes | 104 | 42.3 | 58.7 | ||||
| No | 199 | 13.1 | 34.7 | ||||
| Cutting margin (cm) (n = 224)a | 0.004 | 0.067 | 0.470 | 0.210-1.055 | |||
| < 1 | 187 | 25.7 | 45.5 | ||||
| ≥ 1 | 37 | 10.8 | 18.9 | ||||
HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; WBC, white blood cell; PLT, platelet; AFP, alpha-fetoprotein; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, albumin; PT, prothrombin time; γ-GT, γ-glutamyl transpeptidase; ALP, alkaline phosphatase.
Number of available data.